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Edited by Vladimir SkulachevAbstract The transport of various S-nitrosothiols, NO and NO
donors in human red blood cells (RBC) and the formation of
erythrocytic S-nitrosoglutathione were investigated. Of the NO
species tested only S-nitrosocysteine was found to form S-nitro-
soglutathione in the RBC cytosol. L-Serine, L-cysteine and L-
lysine inhibited formation of S-nitrosoglutathione. Incubation
of RBC pre-incubated with S-[15N]nitroso-L-cysteine with native
plasma or platelet-rich plasma led to formation of S-[15N]nitros-
oalbumin and inhibited platelet aggregation, respectively. The
speciﬁc transporter system of S-nitroso-L-cysteine in the RBC
membrane may have implications for formation of S-nitrosoalbu-
min and S-nitrosohemoglobin and for transport of NO bioactiv-
ity within the vasculature.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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L-Arginine is oxidized by various nitric oxide synthase
(NOS) isozymes to the free-diﬀusible gaseous nitric oxide
(NO). The high aﬃnity of NO to iron in heme-containing pro-
teins determines both its bioactivity and metabolism. From the
quantitative point of view the major metabolic pathway of NO
involves its oxyhemoglobin-catalyzed oxidation to nitrate in
red blood cells (RBC). NO itself is not detectable in human cir-
culation because of its very short half-life (<0.1 s) [1]. In hu-
man blood NO circulates at nM-concentrations in the form
of S-nitrosoproteins, notably S-nitrosoalbumin (SNALB), S-
nitrosohemoglobin (SNOHb) and Fe-nitrosylhemoglobinAbbreviations: GC–MS, gas chromatography-mass spectrometry;
GSNO, S-nitrosoglutathione; GTN, glycerol trinitrate; HbFeNO,
Fe-nitrosylhemoglobin; HMM, high-molecular-mass; HPLC, high-
performance liquid chromatography; LMM, low-molecular-mass; NO,
nitric oxide;NOS,nitric oxide synthase; PPP, platelet-poor-plasma; PRP,
platelet-rich-plasma;RBC, red blood cells; SNAC,S-nitroso-N-acetyl-L-
cysteine; SNALB, S-nitrosoalbumin; SNAP, S-nitroso-N-acetyl-L-
penicillamine; SNC, S-nitrosocysteine; SNhC, S-nitrosohomocysteine;
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doi:10.1016/j.febslet.2005.06.040(HbFeNO) [2]. SNALB [3,4] and SNOHb [5–8] possess NO-
related biological activities such as vasodilation and inhibition
of platelet aggregation [2,9,10]. SNALB is long-lived, i.e., its
half-life in vivo in the rat amounts to several minutes [11]. It
is assumed that SNALB [4] and SNOHb [5,6] are endogenous
pools and transporters of NO bioactivity in human circulation.
The mechanisms leading to SNALB and SNOHb formation
in vivo are largely unknown. In the presence of glutathione
(GSH) at mM-concentrations in NOS incubates, formation
of S-nitrosoglutathione (GSNO) at lM- [12,13] or nM-concen-
trations [14] has been reported. Further mechanisms leading
to S-nitrosothiols could involve formation of SNOHb from
the intramolecular transfer of the +NO group of HbFeNO to
the sulfhydryl group of b-Cys93 of hemoglobin [15], with
HbFeNO being produced from the reaction of NO [15] or ni-
trite [7,8] with hemoglobin. Dinitrogen trioxide (N2O3) derived
from autoxidized NO is discussed as a potent S-nitrosylating
species [16]. Also, serum albumin and other proteins have been
suggested to catalyze formation of low-molecular-mass
(LMM) and high-molecular-mass (HMM) S-nitrosothiols by
oxidizing in the protein hydrophobic core NO to +NO which
is then transferred to the sulfhydryl group of LMM thiols
and other functionalities [17,18]. Eventually, it has been
hypothesized that ceruloplasmin may catalyze S-nitrosothiol
formation [19].
Still much less known are the mechanisms by which HMM
S-nitrosothiols, notably SNOHb and SNALB, develop their
biological actions within various cells such as smooth muscle
cells and blood platelets. In consideration of the potential
involvement of RBC in the formation and metabolism of
endogenous S-nitrosothiols as well as in the export of NO-
bioactivity, we investigated in the present study whether these
processes may be mediated by a speciﬁc transposter system for
LMM S-nitrosothiols in the membrane of human RBC.2. Materials and methods
2.1. Chemicals
L-Cysteine, D-cysteine and N-acetyl-L-cysteine were obtained from
Aldrich (Steinheim, Germany). Glutathione, L-homocysteine and
ADP were purchased from Sigma Chemie (Deisenhofen, Germany).
S-Nitroso-N-acety-L-penicillamine (SNAP) was bought from Biomol
(Hamburg, Germany). Glycerol trinitrate (GTN; 2.2 wt% in glucose)
was obtained from Pohl Boskamp (Hohenlockenstedt, Germany). So-
dium [15N]nitrite (98% at 15N) was purchased form Cambridge Isotopeblished by Elsevier B.V. All rights reserved.
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NO gas and all other chemicals were bought from Merck (Darmstadt,
Germany).Fig. 1. Formation of GSNO in the cytosol of washed human RBC
(1.5 ml) after their incubation for 10 min with various S-nitrosothiols,
NO and NO-donors each at a concentration of 400 lM in physiolog-
ical saline (1.5 ml). Other experimental conditions are described in
Section 2.3. Data are presented as mean ± S.D. (n = 2–5). n.d., not
detected, i.e., GSNO concentration was below 200 nM, which is the
detection limit of the HPLC method used to measure GSNO
concentration [25].2.2. Synthesis and analysis of S-nitrosothiols
Unlabelled and 15N-labelled S-nitrosothiols of LMM thiols were
synthesized by incubation for 5 min at room temperature (22–26 C)
of equal volumes of equimolar deoxygenated aqueous solutions of thi-
ols and [15N]nitrite, and of a 1/10th volume of 4 M HCl. Stock solu-
tions and dilutions in isotonic saline were prepared immediately
prior to start the experiments and stored on ice until use. These S-
nitrosothiol preparations were found not to contain NO and nitrite
by an assay based on the Griess reaction [20] nor thiols by the method
of Ellman [21]. The structure of unlabelled and 15N-labelled LMM S-
nitrosothiols was elucidated by ﬂow injection analysis electrospray ion-
ization mass spectrometry as described previously [22]. Unlabelled and
15N-labelled S-nitrosoalbumin (SNALB and S15NALB, respectively)
were synthezised using freshly obtained human plasma and unlabelled
and 15N-labelled butylnitrite, respectively [23]. SNALB and S15NALB
were isolated from their reaction mixtures by using 5-ml HiTrapBlue
Sepharose aﬃnity columns (Pharmacia, Freiburg, Germany) and con-
centrated by subsequent ultraﬁltration of the eluates using Centrisart I
cartridges (cut-oﬀ, 20 kDa; Sartorius, Go¨ttingen, Germany) [23]. The
concentration of SNALB and S15NALB in these preparations was
determined by gas chromatography–mass spectrometry (GC–MS)
after conversion of the S-nitroso groups to nitrite and [15N]nitrite by
HgCl2, respectively [23]. S
15NALB concentrations in 400-ll aliquots
of plasma samples from incubations of RBC with S-[15N]nitroso-L-cys-
teine (L-S15NC) were determined by GC–MS using SNALB as the
internal standard [24].2.3. Incubation of red blood cells with S-nitrosothiols, NO and NO
donors
All incubation experiments with RBC and plasma were performed
at room temperature (22–26 C). EDTA blood (3-ml aliquots) from
healthy volunteers was centrifuged at 4 C (800 · g, 5 min), and
plasma was completely removed. RBC were washed three times with
5-ml aliquots of physiological saline and centrifuged at 4 C
(800 · g, 5 min). The erythrocyte fraction from the last wash was
incubated with solutions of L-S15NC, other S-nitrosothiols, GTN
or Angelis salt in physiological saline (1.5 ml). In experiments with
NO, this gas was added to a suspension of erythrocytes in physio-
logical saline (3 ml total volume) by means of a gas-tight syringe.
After incubation erythrocytes were washed 5 times with physiologi-
cal saline (3 ml). The erythrocyte fraction from the last centrifuga-
tion was frozen at 80 C for 30 min. Thawed RBC were
resuspended in distilled water (1:1, v/v) for hemolysis. After centri-
fugation at 10 C (800 · g, 40 min), aliquots (1 ml) of the superna-
tant were taken and ultraﬁltered at 4 C (1200 · g, 60 min).
Aliquots (200-ll) of the ultraﬁltrate were analyzed for GS15NO by
high-performance liquid chromatography (HPLC) [25]. In some
experiments erythrocytes were pre-incubated with L-S15NC. After
wash and centrifugation of L-S15NC-treated erythrocytes as de-
scribed above, RBC were incubated with the original plasma. Sub-
sequently, the resulted blood was centrifuged (800 · g, 5 min), and
the plasma obtained was analyzed for S15NALB by GC–MS or used
for measurement of platelet aggregation. Under the experimental
conditions described above loss of S-nitrosothiols cannot be ex-
cluded. However, all experiments were performed in such a way that
loss of S-nitrosothiols was minimum and presumably of the same
extent in a speciﬁc condition.2.4. Measurement of platelet aggregation
Human blood (30 ml, citrate as the anticoagulating agent) was
drawn from antecubital veins of healthy volunteers who did not receive
any medication for at least 10 days before. Platelet-rich plasma (PRP)
and platelet-poor plasma (PPP) were prepared from whole blood by
centrifugation at room temperature for 15 min at 200 · g and
400 · g, respectively [26]. Platelet aggregation measurements were per-
formed in duplicate with 250-ll aliquots of twice washed PRP at 37 C.
Platelet aggregation was induced by ADP (1 lM) and monitored for
5 min by the method of Born and Cross [27] with an Apact dual-chan-
nel aggregometer (LAbor, Hamburg, Germany).3. Results
3.1. GSNO formation in human washed erythrocytes incubated
with various S-nitrosothiols, gaseous NO, GTN and Angeli s
salt
The results of these studies are presented in Fig. 1. Incuba-
tion of washed RBC with GSNO did not result in GSNO for-
mation in the RBC cytosol, suggesting that the RBC
membrane is impermeable to GSNO. Also, incubation of
RBC with S-nitroso-N-acetyl-L-cysteine (SNAC), NO gas,
GTN or Angelis salt did not produce erythrocytic GSNO at
concentrations above 200 nM. Erythrocytic GSNO at the
low concentration of 500 nM was formed after incubation of
RBC with SNAP, which is a potent S-transnitrosylating agent
of L-cysteine, N-acetyl-L-cysteine and GSH [28]. The highest
intracellular GSNO concentrations were obtained from the
incubation of RBC with L-SNC. The D-form of S-nitrosocys-
teine, i.e. D-SNC, led to formation of erythrocytic GSNO at
statistically signiﬁcantly (P < 0.05; t-test) lower concentrations
than L-SNC. Erythrocytic GSNO was also formed from the
incubation of RBC with S-nitroso-L-homocysteine (L-SNhC),
however, at concentrations lower than those formed from D-
SNC.
3.2. Eﬀects of amino acids on S-nitrosocysteine (SNC)-
dependent GSNO formation in washed erythrocytes
The results shown in Fig. 1 suggest that the formation of
GSNO in the cytosol of RBC is dependent upon the transport
of L-SNC through the RBC membrane. Thus, the eﬀect of se-
lected L-amino acids on the L-S15NC-dependent formation of
erythrocytic GS15NO was investigated. L-Cysteine, L-serine
and L-lysine were found to inhibit formation of intracellular
GS15NO from the incubation of RBC with L-S15NC (Fig.
2A). The most potent inhibitor was found to be L-serine
(98 ± 5 %) followed by L-cysteine (80 ± 15 %) and L-lysine
(65 ± 10 %). Fig. 2B shows that the concomitant appearance
in the RBC cytosol of GSNO and L-cysteine upon incubation
with L-SNC is inhibited by L-serine in a concentration depen-
dent manner. Erythrocytic L-cysteine concentrations were con-
stantly higher than GSNO concentrations both in the absence
and in the presence of L-serine (Fig. 2B).
Fig. 2. Eﬀect of L-amino acids on GS15NO formation in washed RBC
(1.5 ml) incubated with L-S15NC in physiological saline (1.5 ml). (A)
Inhibition of GS15NO in the cytosol of washed erythrocytes after 5 min
of co-incubation with L-S15NC (600 lM) and the shown amino acid
(each at 10 mM). Control: Incubation of RBC with L-S15NC in the
absence of amino acids. Data are presented as mean ± S.D. (n = 2–5).
(B) Intracellular GSNO and L-cysteine formation in washed RBC after
5 min of incubation with L-SNC (600 lM) in the presence of L-serine
at varying concentrations (0–10 mM). Experimental conditions are
described in Section 2.3.
Fig. 3. Concentration course of L-cysteine in the cytosol upon
incubation of washed RBC (1.5 ml) with varying concentrations of
L-SNC or L-cysteine in physiological saline (1.5 ml) for 3 min.
Erythrocytic L-cysteine concentration in washed and lyzed RBC was
determined by HPLC (mobile phase pH 2) as described [25].
Experimental conditions are described in Section 2.3.
Fig. 4. Initial formation rates of GSNO and L-cysteine in the cytosol
of washed RBC (1.5 ml) after 3-min incubation with diﬀerent
concentrations of L-SNC (0–2 mM) in physiological saline (1.5 ml).
KM and Vmax (with regard to cytosolic L-cysteine concentration) were
estimated graphically. Cytosolic GSNO (mobile phase pH 7) and L-
cysteine (mobile phase 2) were determined by HPLC [25]. Experimen-
tal conditions are described in Section 2.3.
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RBC
RBC were incubated with varying concentrations of L-SNC
or L-cysteine and the concentration of L-cysteine in the cytosol
was determined. Fig. 3 shows that cytosolic L-cysteine concen-
tration was clearly higher upon RBC incubation with L-SNC
than that obtained upon RBC incubation with L-cysteine.
The course of intracellular L-cysteine concentration suggests
that the transport both of L-SNC and L-cysteine through the
RBC membrane is saturable.
3.4. Kinetics of L-SNC transport in washed erythrocytes
RBC were incubated for 3 min with varying concentrations
of L-SNC. The concentration of L-cysteine and GSNO in the
cytosol was determined by HPLC and the respective initial for-
mation rates were calculated and plotted versus L-SNC con-centration (Fig. 4). The maximum initial velocity (Vmax) of
L-cysteine and GSNO in the RBC cytosol were determined
to be 95 and 15 lM/min, respectively. The ‘‘Michaelis–Men-
ten’’ constant KM was calculated to be 470 lM of L-SNC with
respect to L-cysteine and 800 lM of L-SNC with respect to
GSNO.
3.5. Formation of plasmatic S15NALB upon incubation of
L-S15NC with whole blood and washed RBC
Incubation of human whole blood with varying concentra-
tions of L-S15NC led to formation of GS15NO and L-cysteine
in the cytosol of RBC and of S15NALB in the plasma in a
4122 J. Sandmann et al. / FEBS Letters 579 (2005) 4119–4124concentration dependent manner (Fig. 5). Plasmatic S15NALB
concentrations were at least 10 times higher than erythrocytic
GS15NO concentrations.
Incubation of the original plasma with washed RBC, which
had been incubated before with varying concentrations of L-
S15NC, led to formation of S15NALB in the plasma in a con-
centration dependent manner (Fig. 6). The concentration of
GS15NO in the RBC cytosol (Fig. 5B) was of the same order
of the S15NALB concentration in the plasma (Fig. 6).
3.6. Inhibition of ADP-induced human platelet aggregation by
human RBC preincubated with L-S15NC
ADP-induced platelet aggregation was not inhibited by
washed human RBC, which had been pre-incubated with phys-Fig. 5. (A) Formation of cytosolic GS15NO and L-cysteine as well as
plasmatic S15NALB after incubation of whole blood (3 ml; EDTA as
anticoagulant) with varying concentrations of L-S15NC for 20 min.
Incubation was terminated by centrifugation of the blood (4 C,
800 · g, 10 min). Erythrocytes were washed and lyzed as described in
Section 2. Cytosolic GS15NO, L-cysteine and GSH were determined by
HPLC [25]. S15NALB in plasma (400-ll aliquot) was determined by
GC–MS [24]. (B) Magniﬁcation of the GS15NO course by a factor of
50.
Fig. 6. Formation of plasmatic S15NALB upon incubation of plasma
with RBC previously incubated with L-S15NC. Human blood (EDTA
as an anticoagulant) was centrifuged (4 C, 800 · g, 10 min). RBC were
washed and 1.5-ml aliquots were incubated for 10 min with L-S15NC in
physiological saline (1.5 ml) at the indicated concentrations. After
repeated washing of L-S15NC-treated erythrocytes, RBC (approxi-
mately 1.5 ml) were re-incubated with the original plasma (1.5 ml) for
10 min. After centrifugation of the blood (4 C, 800 · g, 10 min),
S15NALB was extracted from 400-ll aliquots of plasma and quantiﬁed
by GC–MS [24].iological saline in the absence or in the presence of L-cysteine.
L-SNC is a potent inhibitor of platelet aggregation [26]. L-
S15NC potently inhibited ADP-induced platelet aggregation
(Fig. 7). ADP-induced platelet aggregation was inhibited by
washed RBC, which had been incubated before with L-
S15NC (Fig. 7). Inhibition of platelet aggregation by authentic
L-SNC [26] and by L-S15NC-treated washed RBC required
external addition of L-cysteine.4. Discussion
The largest portion of NO imported into RBC is oxidized to
nitrate by oxyhemoglobin. This reaction represents the most
eﬀective physiological inactivation pathway of the potent vaso-
active NOmolecule [29]. Although a comparatively much smal-
ler portion of imported NO is converted to HbFeNO and
subsequently to SNOHb, this fate of NO may powerfully con-
tribute to NO-related biological actions in the vasculature
including inhibition of platelet aggregation [6] and vasodilation
[30]. It has been shown that RBCmay export NO bioactivity by
means of a mechanism that involves S-transnitrosylation of cys-
teine residues in the hemoglobin-binding cytoplasmic domain
of the anion exchanger AE1, i.e., through formation of AE1-
SNO at the membrane-cytosol interface of RBC [30]. Thus
far, it has not been shown that the same mechanism may also
serve to import NO bioactivity from plasma into RBC. The re-
sults of the present study argue against this possibility.
In the present article, we provide evidence that human RBC
possess an alternative mechanism by which NO bioactivity
may be imported from plasma into RBC as well as be exported
Fig. 7. Inhibition of platelet aggregation in PRP (0.25 ml) by (b) L-
S15NC (10 lM) serving as positive control [26], and inhibition of
platelet aggregation in PRP (3 ml) after incubation for 15 min with
washed human RBC (3 ml), which had been pre-incubated for 20 min
with (a) L-S15NC (400 lM) in saline (3 ml) or (c) saline (control, 3 ml).
Platelet aggregation was induced by addition of ADP (1 lM). The
extent of aggregation of the control was set to 100%. Values are shown
as means ± S.D. from two experiments using blood from two healthy
volunteers who had not taken aspirin or other drugs inhibiting platelet
aggregation for the last 10 days. (A) Relative aggregation. (B) Original
aggregation curves obtained from the experiments with the blood of
one volunteer. In all platelet aggregation measurements L-cysteine was
externally added at 10 lM.
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siderably lesser extent its D-isoform, i.e., D-SNC, and the struc-
turally closely related S-nitrosohomocysteine (SNhC), but not
GSNO or SNAC, are transported through the membrane of
washed human RBC, strongly suggests that a speciﬁc transpos-
ter system for L-SNC physiologically exists within the RBC
membrane. The speciﬁc transmembraneous transport of L-
SNC in human RBC may be a rationale to explain both the
formation of SNALB from erythrocytic SNOHb and the for-
mation of erythrocytic SNOHb from plasmatic S-nitrosothiolssuch as SNALB. Such a transporter system may also explain
the oxidative metabolism of plasmatic S-nitrosothiols to ni-
trate within RBC [31] via S-transnitrosylation reactions that
yield L-SNC [28,32]. Certainly, we can not exclude the possibil-
ity that in our study erythrocytic S-nitrosothiols were also
partly exported into the plasma by the anion exchanger AE1.
GSH and hemoglobin are the most abundant thiols in the
cytosol of RBC (present at mM-concentrations), with hemo-
globin-sulfhydryl groups being in approximately 10-fold excess
of GSH-sulfhydryl groups. On arrival in the RBC cytosol, the
+NO group of L-SNC will be transferred almost quantitatively
to the sulfhydryl groups of GSH and hemoglobin to form
GSNO and SNOHb, respectively. As S-transnitrosylation
reactions are rapid and reversible reactions [28,33], it can be
reasonably be expected that the transmembraneous transport
of L-SNC will be rate-limiting. Furthermore, we may expect
that in equilibrium SNOHb will be the most abundant S-nitro-
sothiol in the cytosol of RBC, followed by GSNO and L-SNC.
Indeed, L-SNC concentration in the RBC cytosol upon incuba-
tion with L-SNC never exceeded 5 lM in our experiments. In
the present study we did not measure erythrocytic SNOHb.
Incubation of human whole blood with S-nitrosocysteine (at
10 mM) for 3 h at 4 C has been shown to produce erythrocytic
SNOHb at 220 lM, but undetectable amounts of HbFeNO
[34]. Such a distribution may explain the ﬁnding of our study
that in the RBC cytosol GSNO concentration was consider-
ably lower than L-cysteine concentration.
The transport of L-SNC into the RBC cytosol and the sub-
sequent formation of L-cysteine proceeded more rapidly than
the transport of L-cysteine. Amino acids such as L-cysteine,
L-serine and L-lysine inhibited intracellular formation of
GSNO upon incubation of washed RBC with L-SNC. Whether
L-SNC uses the same RBC membrane transporter system,
which is responsible for L-amino acids, i.e., the L-AT [32], re-
mains to be elucidated. More detailed knowledge of this trans-
porter system may be of particular importance for a better
understanding of the role of S-nitrosothiols and RBC in health
and NO-related dysfunctions. Also, it remains to be investi-
gated whether this transporter system may be modulated by
pharmacological intervention in favor of NO bioactivity. The
15N-labelling technique applied in the present study may help
answer these questions and may also help solve the critically
important controversy over the mechanisms by which erythro-
cytic SNOHb releases NO [2,9].
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